Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group
... Nephrologists report that barriers to increased use of both Zemplar and Genzyme's Hectorol in CKD center around reimbursement and incidences of
hypercalcemia and hyperphosphatemia. Amgen's Sensipar continues to be used in less than one third of dialysis patients, although Nephrologists continue to project ...
Cytochroma Announces Positive Comparative Data on CTA018 in Chronic Kidney Disease Model
... CTA018 has significantly reduced
activity and half-life in human enterocytes (intestinal cells), making
CTA018 Injection far less likely to cause
hypercalcemia (excessive blood
calcium) or hyperphosphatemia (excessive blood phosphorus).
(3) CTA018 Preserves Vitamin D Status
Currently available vitamin D ...
FDA Accepts Genta's NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with
cancer-related
hypercalcemia that is resistant to hydration. The Company
has developed G4544, an oral formulation of the active ingredient in
Ganite, that has recently entered ...
Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with
cancer-related
hypercalcemia that is resistant to hydration. The Company
has developed G4544, an oral formulation of the active ingredient in
Ganite, which has recently entered ...
Firefly genes allow testing of new therapy against lymphoma
... so, the researchers developed what they hope will be the first animal model for the disease that includes a severe bone depletion called humoral
hypercalcemia of malignancy (HHM), a condition that can affect four out of every five ATLL patients and shorten their lives.
The study is published in the ...
Bradley Pharmaceuticals to Feature Elestrin(TM) at North American Menopause Society Annual Meeting
... increase in gallbladder disease requiring surgery in postmenopausal
women receiving estrogens has been reported. Estrogen therapy may lead to
severe
hypercalcemia in patients with breast cancer and bone metastases.
Retinal vascular thrombosis has been reported in patients receiving
estrogens. Estrogen products ...
Novartis files application with FDA for Zometa
... by the FDA just two weeks ago (20 August 2001) for the treatment of
hypercalcemia of malignancy (HCM), the most common life-threatening metabolic ... Novartis has received marketing clearances for Zometa in the treatment of
hypercalcemia of malignancy (HCM) in more than 30 countries.
"Bone complications ...
Hypercalcemia in Medical Technology
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
... groups. In addition, the occurrence of
hypercalcemia was half that of Forteo(R) in the highest dose of ... sites with less resorptive effect and less
hypercalcemia compared to PTH and its analogs," said Louis ... do not stimulate adverse bone resorption and
hypercalcemia to the same extent as PTH, highlighting differing ...
Genta Clinical Programs Featured at American Society of Hematology Meeting
... by also stimulating bone formation. In patients
with cancer-related
hypercalcemia who were resistant to hydration,
randomized double-blind trials have been ... in the U.S. for treatment of symptomatic patients with cancer
related
hypercalcemia that is resistant to hydration. The Company has
developed G4544, an oral ...
Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
... this condition can quickly become lethal. In
patients with cancer-related
hypercalcemia who were resistant to hydration,
randomized double-blind trials have been ... in the U.S. for treatment of symptomatic patients with cancer
related
hypercalcemia that is resistant to hydration. The Company has
developed G4544, an oral ...
Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
... by Genta and approved in the U.S. for treatment of
cancer- related
hypercalcemia that is resistant to hydration. The initial
clinical study is a ... this condition can quickly become lethal. In
patients with cancer-related
hypercalcemia who were resistant to hydration,
randomized double-blind trials have been ...
New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
... serious risks reported with estrogen therapy include
certain cardiovascular disorders, certain malignant neoplasms, dementia,
gallbladder disease,
hypercalcemia and visual abnormalities. The most
frequently reported adverse events in Divigel(R) clinical trials were
nasopharyngitis, upper respiratory tract ...
Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with
cancer-related
hypercalcemia that is resistant to hydration. The Company
has developed G4544, an oral formulation of the active ingredient in
Ganite, that has recently entered ...
FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with
cancer-related
hypercalcemia that is resistant to hydration. The Company
has developed G4544, an oral formulation of the active ingredient in
Ganite, that has recently entered ...
Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with cancer
related
hypercalcemia that is resistant to hydration. The Company has
developed G4544, an oral formulation of the active ingredient in Ganite,
that has recently entered ...
Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with cancer
related
hypercalcemia that is resistant to hydration. The Company has
developed G4544, an oral formulation of the active ingredient in Ganite,
that has recently entered ...
Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with cancer
related
hypercalcemia that is resistant to hydration. The Company has
developed G4544, an oral formulation of the active ingredient in Ganite,
that has recently entered ...
Hypercalcemia in Medical Products
MM-PTH RIA Test
Description:... in serum and urine. PTH is helpful in discriminating between primary hyperparathyroidism, where PTH levels are elevated, and nonparathyroid
hypercalcemia [3,4]. Additionally, PTH is helpful for assessing parathyroid function in renal failure and is often used for dialysis patients.
Endres DB, et ...
Company:Diagnostic Systems Laboratories, Inc.
C-PTH RIA Test
Description:... in serum and urine. PTH is helpful in discriminating between primary hyperparathyroidism, where PTH levels are elevated, and nonparathyroid
hypercalcemia [3,4]. Additionally, PTH is helpful for assessing parathyroid function in renal failure and is often used for dialysis patients.
Endres DB, et ...
Company:Diagnostic Systems Laboratories, Inc.
I-PTH IRMA Test
Description:... in serum and urine. PTH is helpful in discriminating between primary hyperparathyroidism, where PTH levels are elevated, and nonparathyroid
hypercalcemia [3,4]. Additionally, PTH is helpful for assessing parathyroid function in renal failure and is often used for dialysis patients.
Endres DB, et ...
Company:Diagnostic Systems Laboratories, Inc.
I-PTH ELISA Test
Description:... in serum and urine. PTH is helpful in discriminating between primary hyperparathyroidism, where PTH levels are elevated, and nonparathyroid
hypercalcemia [3,4]. Additionally, PTH is helpful for assessing parathyroid function in renal failure and is often used for dialysis patients.
Endres DB, et ...
Company:Diagnostic Systems Laboratories, Inc.
Hypercalcemia in Medical Dictionary
Hypercalcemia
...
hypercalcemia - An abnormally elevated blood calcium . ... is in the range of 8.5 to 10.5 mg/dl.
hypercalcemia (high calcium levels) Q. What is
hypercalcemia ? What causes it? No name/ No state given ... ...
Ascorbic acid
... cause toxic ity because, as a water-soluble vitamin , it is simply excreted in the urine . Ascorbic acid Another name for vitamin C .
hypercalcemia Hypercalcemia is a condition marked by abnormally high levels of calcium in the blood . It is an issue during vitamin D toxic ity. ...
Calcium phosphate
... calcium makes bone strong yet flexible to withstand stress . Sudden
hypercalcemia can cause vomiting and coma , while prolonged and moderate
hypercalcemia results in the deposit of calcium phosphate crystals in the kidney s ...
Bloating
... [1-3] Nausea , vomiting , abdominal cramp ing and/or bloating , constipation , hypotension , hyperglycemia , generalized weakness , and
hypercalcemia have been associated with the use of powdered shark cartilage . A group of symptoms such as gas, bloating , abdominal pain , and diarrhea ...
Bulimia
... or anxiety drugs such as digit alis, amphetamine s, and anti tumor medicines ( chemotherapy ) a high level of calcium in the blood (
hypercalcemia ) ... Bupropion should not be taken by patients with a history of seizures , high blood pressure , anorexia , or bulimia nervosa . In ...
Calcium
... channel blockers , which relax blood vessels and increase the supply of blood and oxygen to the heart , while reducing its workload; ...
hypercalcemia - An abnormally elevated blood calcium . Normal blood calcium is in the range of 8.5 to 10.5 mg/dl. Children with low levels of lead ...
Coma
... either in an irreversible coma or has less than six months to live and is unable to make medical decisions. The natural course of untreated
hypercalcemia progresses to loss of consciousness and coma . This may be preferred by some patients at the end of life who have unrelieved suffering and/or ...
Consciousness
... features: loss of consciousness , amnesia , seizure , or a change in mentation. See brain contusion . The natural course of untreated
hypercalcemia progresses to loss of consciousness and coma . This may be preferred by some patients at the end of life who have unrelieved suffering and/or ...
Conscious
... "frame," be conscious of your frame throughout the workout and try to stay within your frame for best results. The natural course of untreated
hypercalcemia progresses to loss of conscious ness and coma . This may be preferred by some patients at the end of life who have unrelieved suffering and/or ...
Digit
... fingernails, ... drugs such as digit alis, amphetamine s, and anti tumor medicines ( chemotherapy ) a high level of calcium in the blood (
hypercalcemia ) a low level of potassium in the blood ( hypokalemia ) alcohol abuse viral hepatitis (an infection of the liver ) ... Digit al ...
More>>
Hypercalcemia in Biological News
Gallium: A new antibacterial agent?
... inhalation of Ga protected mice from both acute and chronic P. aeruginonsa lung infections. As Ga is already FDA approved for the treatment of
hypercalcemia of malignancy, these data suggest that Ga might be a promising new therapeutic for the treatment of infection with P. aeruginonsa, a major cause of ...
Hypercalcemia in Biological Technology
Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with
cancer-related
hypercalcemia that is resistant to hydration. The Company
has developed G4544, an oral formulation of the active ingredient in
Ganite, that has recently entered ...
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with
cancer-related
hypercalcemia that is resistant to hydration. The Company
has developed G4544, an oral formulation of the active ingredient in
Ganite, that has recently entered ...
Genta Announces Second Quarter 2008 Financial Results and Conference Call
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with
cancer-related
hypercalcemia that is resistant to hydration. The Company
has developed G4544, an oral formulation of the active ingredient in
Ganite, that has recently entered ...
Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
... should always be started at the lowest possible dose
and should not be increased without careful monitoring of serum calcium. In
order to avoid
hypercalcemia and related conditions, the optimal daily dose
of ROCALTROL must be carefully determined for each patient. The safety and
effectiveness of ROCALTROL ...
Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
... (gallium nitrate injection), which the
Company is exclusively marketing in the U.S. for treatment of symptomatic
patients with cancer-related
hypercalcemia that is resistant to hydration.
The Company has developed G4544, an oral formulation of the active
ingredient in Ganite, that has recently entered ...
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with
cancer-related
hypercalcemia that is resistant to hydration. The Company
has developed G4544, an oral formulation of the active ingredient in
Ganite, that has recently entered ...
Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with cancer
related
hypercalcemia that is resistant to hydration. The Company has
developed G4544, an oral formulation of the active ingredient in Ganite,
that has recently entered ...
Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with cancer
related
hypercalcemia that is resistant to hydration. The Company has
developed G4544, an oral formulation of the active ingredient in Ganite,
that has recently entered ...
Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with cancer
related
hypercalcemia that is resistant to hydration. The Company has
developed G4544, an oral formulation of the active ingredient in Ganite,
that has recently entered ...
Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
... (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with cancer
related
hypercalcemia that is resistant to hydration. The Company has
developed G4544, an oral formulation of the active ingredient in Ganite,
that has recently entered ...